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Researchers navigate the ocean of biomarkers searching for
proper targets and optimal utilization of them. Emergency
medicine builds up the front line to maximize the utility
of clinically validated biomarkers and is the cutting edge
field to test the applicability of promising biomarkers
emerging from thorough translational researches. The role
of biomarkers in clinical decision making would be of
greater significance for identification, risk stratification,
monitoring, and prognostication of the patients in the
critical- and acute-care settings. No doubt basic research
to explore novel biomarkers in relation to the pathogenesis
is as important as its clinical counterpart. This special
issue includes five selected research papers that cover a
variety of biomarker- and disease-related topics.
The paper by N. Shi et al. demonstrated that the plasma
microRNA-127 (miR-127) level was significantly downregu-
lated in acute pancreatitis (AP) patients with respiratory
failure compared with the healthy volunteers and those
without respiratory failure. It was the first study that
integrated miR-127 and the inflammatory injuries of the
pancreas and the lung. miR-127 might serve as a potential
marker for the identification of AP with lung injury.
The paper by L.-J. Chen et al. explored the association
between plasma miRNA-24-3p (miR-24) expression and
coagulation factor X (FX) and XII (FXII) levels in major
trauma and trauma-induced coagulopathy (TIC) patients.
In their study, miR-24 was overexpressed in major trauma
and TIC patients, and miR-24 expression correlated with
FX level negatively, suggesting the possibility that miR-24
might inhibit the synthesis of FX during TIC.
P. Lochner et al. measured osteopontin (OPN: biomarker
for inflammation) and neurofilament heavy chain (NfH:
biomarker for axonal injury) in patients with acute optic
neuritis and sex- and age-matched healthy controls. They
demonstrated that OPN and NfH are elevated in these
patients, supporting the presence of underlying inflamma-
tion and axonal injury as well as the prognostic utility of
examining biomarkers in optic neuritis.
The paper by B. Morawiec et al. addressed the prognostic
value of copeptin in patients admitted with chest pain and
suspected acute coronary syndrome (ACS). They concluded
that copeptin appears to be an independent predictor of
long-term mortality in patients with suspected ACS. Copep-
tin may be also considered as an early marker for identifying
high-risk patients who would develop heart failure.
The last paper by C. Spiekermann et al. explored S100
proteins A8 and A9 (S100A8/A9) as a promising diagnostic
marker for peritonsillar abscess (PTA). Using a combination
of S100A8/A9 levels and characteristic symptoms of PTA,
they also developed a PTA score as an objective and appro-
priate tool to differentiate between peritonsillitis and PTA.
We hope that this special issue would bridge basic
research and clinical practice on biomarkers, facilitate the
scientific development in this research field, and eventually
contribute to the unrivaled value of disease markers.
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